lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
282 rows where filing_period = "second_quarter", filing_year = 2018 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2139597 | ACG ADVOCACY 550104f5-fad6-4271-872e-e28b06aeb8cb | 2T | ACG ADVOCACY | 2057 | ROIVANT SCIENCES, INC. | 2018 | second_quarter | PHA | Drug Pricing. Innovation Issues. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2018-06-29T13:56:42.033000-04:00 | |
| 2139890 | SIMS STRATEGIES, LLC b3d32ba9-f00a-49d5-bb5a-96744e8e5eea | Q2 | SIMS STRATEGIES, LLC | 401104546 | AMAG PHARMACEUTICAL | 2018 | second_quarter | PHA | Education on products and issues related to women's health. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-02T13:59:20.760000-04:00 | |
| 2139894 | SIMS STRATEGIES, LLC d4137da8-b534-474b-b17d-6f57bde6ecb3 | Q2 | SIMS STRATEGIES, LLC | 401104546 | GLAXOSMITHKLINE, INC. | 2018 | second_quarter | PHA | Education and importance of various pharmaceutical industry issues, including issues affecting vaccines. | SENATE | 40000 | 0 | 0 | 2018-07-02T14:02:24.463000-04:00 | |
| 2140937 | CHATMAN, LLC e0ee2783-0f8c-490c-bfc5-03fc2a4882c4 | Q2 | CHATMAN, LLC | 400678024 | LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER | 2018 | second_quarter | PHA | Support continuation of Pharmacy 340B program in HRSA. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-07-08T22:33:50.067000-04:00 | |
| 2140980 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER afd75a50-5f71-4808-acba-2c9381020ca4 | Q2 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2018 | second_quarter | PHA | 340B drug pricing, PREA, CAR-T | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 52635 | 0 | 0 | 2018-07-09T10:41:45.093000-04:00 | |
| 2141153 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 9044ccfd-ffd6-4b08-a6dd-95d792120d95 | Q2 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 401103437 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 2018 | second_quarter | PHA | FDA Listening Session on Compounding | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 10000 | 0 | 0 | 2018-07-09T14:56:20.210000-04:00 | |
| 2141215 | THE METROHEALTH SYSTEM 484fe8a3-543d-4e8c-ae76-8ca8c172c9ce | Q2 | THE METROHEALTH SYSTEM | 288236 | THE METROHEALTH SYSTEM | 2018 | second_quarter | PHA | 340B | HOUSE OF REPRESENTATIVES,SENATE | 7500 | 0 | 0 | 2018-07-09T16:06:24.423000-04:00 | |
| 2141252 | AMERICAN CAPITOL GROUP 2cdf0715-a9b2-43b7-a618-060bf92aac4a | Q2 | AMERICAN CAPITOL GROUP | 305852 | CARDINAL HEALTH | 2018 | second_quarter | PHA | Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2018-07-09T16:35:56.473000-04:00 | |
| 2141408 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ad8b1f52-6f07-4d57-85ff-e945c161659f | Q2 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018 | second_quarter | PHA | Compounding of radiopharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 30000 | 0 | 0 | 2018-07-10T09:14:04.747000-04:00 | |
| 2141594 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 289ad1b1-c233-4448-9995-2f69857f4025 | Q2 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2018 | second_quarter | PHA | Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-10T11:50:13.263000-04:00 | |
| 2141776 | AMERICAN COLLEGE OF CLINICAL PHARMACY 78d3484b-36d1-4e62-8af4-f91cdfdc35f8 | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2018 | second_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2018-07-10T15:03:15.193000-04:00 | |
| 2142003 | HOLLAND & KNIGHT LLP d86d1c92-11bd-4e05-8c0b-a4e76dc15a1b | Q2 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2018 | second_quarter | PHA | Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act; H.R. 3964, Opioid Addiction Prevention Act of 2017; H.R. 2063, Opioid PACE Act of 2017. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2018-07-11T09:10:07.070000-04:00 | |
| 2142008 | HOLLAND & KNIGHT LLP e800053c-1a7a-415f-bfa3-1bfee0262f94 | Q2 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2018 | second_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2018-07-11T09:19:11.633000-04:00 | |
| 2142403 | RED+BLUE STRATEGIES 5eb546a3-9290-464d-b966-2615f78cfe9a | Q2 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2018 | second_quarter | PHA | S. 2553 - Know the Lowest Price Act of 2018- Support of the elimination of "gag clauses" in Medicare Part D. S. 2554 - Patient Right to Know Act - Support of the elimination of "gag clauses" in private market drug benefits. H.R. 6 - Support for Patients and Communities Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 3120 - Helping to End Addition and Lessen Substance Use Disorders Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 2460/H.R. 3528 - Every Prescription Conveyed Securely Act - support for a bill that would require electronic prescribing for opioids. CMS regulations related to the Medicare Part D program and role of Prescription Drug Plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. The Trump Administration's Blueprint for Controlling Prescription Drug Prices - Issues related to the role PBMs can play in controlling the price of prescription medications in the United States. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-11T14:19:48.077000-04:00 | |
| 2142475 | RED+BLUE STRATEGIES 6734889f-147f-47ab-b003-898c4db37d1b | Q2 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2018 | second_quarter | PHA | H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program. S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs). S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-11T14:51:17.677000-04:00 | |
| 2142506 | KOUNTOUPES DENHAM CARR & REID, LLC 3aab16f3-edc1-4dc8-bb82-ccb8b987ed62 | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2018 | second_quarter | PHA | General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-11T15:12:58.163000-04:00 | |
| 2142509 | RED+BLUE STRATEGIES 5d6ec848-ca51-40b7-ab06-488767191cc8 | Q2 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2018 | second_quarter | PHA | H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 2315 - The Over the Counter Drug Safety Innovation and Reform Act - Support for amending and improving OTC Monograph Reform. S. 2852 - the Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to the continues attention required to antibiotic resistance as a public health threat and policies to ensure the adequacy and development of antibiotics to ward against threats to the common good. Trump Administration's Blueprint for lowering the price of prescription medications in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to over the counter medications and supplements. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 30000 | 0 | 0 | 2018-07-11T15:12:59.600000-04:00 | |
| 2142781 | APOTEX CORP. e91b492c-3c69-40e2-8f70-82ef2d73a690 | Q2 | APOTEX CORP. | 310973 | APOTEX CORP. | 2018 | second_quarter | PHA | S. 974/H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods; Federal policy relating to the Trump Administration's Fiscal Year 2019 Budget proposal to address pharmaceutical market blockages caused by parked Hatch-Waxman 180 day exclusivity periods; S. 124, the Preserve Access to Affordable Generics Act, provisions relating to pharmaceutical patent settlements between generic and brand drug manufacturers; and Federal policy relating to the impact of rebates on the development of the biosimilars market. | HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2018-07-12T09:42:19.997000-04:00 | |
| 2142898 | TAUZIN STRATEGIC NETWORKS 13a911f7-dbee-49ff-96dc-7d4da5caea73 | Q2 | TAUZIN STRATEGIC NETWORKS | 400786367 | CAPTURERX | 2018 | second_quarter | PHA | Issues related to the 340b program | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-12T11:20:39.507000-04:00 | |
| 2142971 | BROWN RUDNICK LLP a72d2d6f-2e91-4d22-b746-32ada8cd5254 | Q2 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2018 | second_quarter | PHA | Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-12T11:56:32.697000-04:00 | |
| 2143054 | BROWN RUDNICK LLP ebf39b3f-bda8-48bb-afdc-761129fa423e | Q2 | BROWN RUDNICK LLP | 287895 | PRIME THERAPEUTICS | 2018 | second_quarter | PHA | S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-12T13:30:34.787000-04:00 | |
| 2143252 | KOUNTOUPES DENHAM CARR & REID, LLC 65dbf30f-1415-4975-a832-abf2079c834c | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2018 | second_quarter | PHA | General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-12T16:09:25.767000-04:00 | |
| 2143288 | KOUNTOUPES DENHAM CARR & REID, LLC 3ad05305-318d-46db-bf80-77f77fb9ef9a | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2018 | second_quarter | PHA | General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of the Vice President of the United States,SENATE,White House Office | 50000 | 0 | 0 | 2018-07-12T16:45:54.800000-04:00 | |
| 2143338 | KOUNTOUPES DENHAM CARR & REID, LLC e81bebdd-7d53-46a5-a176-888f5a7ef1fb | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | 2018 | second_quarter | PHA | Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-12T17:36:27.790000-04:00 | |
| 2143347 | ACADEMY OF MANAGED CARE PHARMACY a13144f9-c7b6-43f1-8ac5-c19d0452c43c | Q2 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2018 | second_quarter | PHA | Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. | HOUSE OF REPRESENTATIVES,SENATE | 85000 | 0 | 0 | 2018-07-12T18:16:36.407000-04:00 | |
| 2143394 | MCDERMOTT+ LLC 3158c8a3-6576-4fe4-9431-bcca499c60a6 | Q2 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2018 | second_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-13T08:59:11.907000-04:00 | |
| 2143463 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 99387ac3-74f5-4a5a-aa57-22077cf02108 | Q2 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2018 | second_quarter | PHA | HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HR 6082 Overdose Prevention and Patient Safety Act; support treatment options/funding for reduction and treatment of opioid addiction. | HOUSE OF REPRESENTATIVES,SENATE | 10452 | 0 | 0 | 2018-07-13T10:09:00.450000-04:00 | |
| 2143515 | MS. TAMI WAHL d9625fe6-46dc-456e-8b4f-4121ff868ce3 | Q2 | MS. TAMI WAHL | 401104405 | ROCK & ASSOCIATES | 2018 | second_quarter | PHA | Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-07-13T10:40:36.687000-04:00 | |
| 2143775 | KOUNTOUPES DENHAM CARR & REID, LLC c6f0a95a-9e81-45c2-a457-5c7085445712 | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2018 | second_quarter | PHA | Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of the Vice President of the United States,SENATE,White House Office | 60000 | 0 | 0 | 2018-07-13T12:39:35.513000-04:00 | |
| 2143979 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 3f41dcd1-ca24-4921-85ff-be7414bd576e | Q2 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2018 | second_quarter | PHA | Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval | Commerce, Dept of (DOC),Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,State, Dept of (DOS),Treasury, Dept of | 420000 | 0 | 0 | 2018-07-13T15:16:47.237000-04:00 | |
| 2144254 | LINCOLN PARK GROUP L.L.C. 5dc944ad-7aa0-4944-b2e8-52f25b5567dc | Q2 | LINCOLN PARK GROUP L.L.C. | 401104374 | PD FRAZER CONSULTING, INC. ON BEHALF OF CANADA INTERNATIONAL PHARMACY ASSOC. | 2018 | second_quarter | PHA | Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act; HR 5752 Stop Illicit Drug Importation Act. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-07-13T18:01:39.083000-04:00 | |
| 2144275 | ASCENSION HEALTH 8fa71f98-0268-48e3-afdd-c093324e5141 | Q2 | ASCENSION HEALTH | 53301 | ASCENSION HEALTH | 2018 | second_quarter | PHA | Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act; Drug pricing; 340B Drug Discount Program; | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 390000 | 0 | 0 | 2018-07-13T21:17:07.513000-04:00 | |
| 2144455 | CONNECT 4 STRATEGIES, LLC fd376fc9-12cf-4752-90ca-9fbf8a96d471 | Q2 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2018 | second_quarter | PHA | s916 Access to Emergency Medications Act Medication assisted therapy - opioids | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-15T09:19:03.450000-04:00 | |
| 2144503 | INDEPENDENT PHARMACY COOPERATIVE cebf9726-4632-4aee-9c89-51e1cf926137 | Q2 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2018 | second_quarter | PHA | Medicare CONTRACT YEAR 2019 POLICY AND TECHNICAL CHANGES comments. Support all drug price concessions at the point of sale. Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-15T15:59:48.480000-04:00 | |
| 2144651 | MCDERMOTT WILL & SCHULTE LLP c41b5d6b-03ab-45b7-bb59-cdee5f64a3c1 | Q2 | MCDERMOTT WILL & SCHULTE LLP | 24338 | MAXOR NATIONAL PHARMACY SERVICES, LLC | 2018 | second_quarter | PHA | Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 50000 | 0 | 0 | 2018-07-16T09:55:31.357000-04:00 | |
| 2144775 | CAPITOL STRATEGIES GROUP, LLC 5dfcf045-56e6-4606-ac8e-921cc84ac3d1 | Q2 | CAPITOL STRATEGIES GROUP, LLC | 400462294 | PHRMA (ON BEHALF OF WE WORK FOR HEALTH ) | 2018 | second_quarter | PHA | Medical Innovation, Medicare Part B and and IPAB | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-16T10:30:41.283000-04:00 | |
| 2144958 | THE KUTLER GROUP d41936fd-3443-41bb-87f6-d0fb9d4ef0e6 | Q2 | THE KUTLER GROUP | 401103966 | PRIME THERAPEUTICS | 2018 | second_quarter | PHA | Patient Right to Know Drug Prices Act Prescription Transparency Act CREATES Act | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 0 | 2018-07-16T11:57:40.083000-04:00 | |
| 2145130 | ACADEMY OF MANAGED CARE PHARMACY 34daf584-f4b1-435b-87e5-1a46fbc46208 | 2A | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2018 | second_quarter | PHA | Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 85000 | 0 | 0 | 2018-07-16T12:53:22.087000-04:00 | |
| 2145354 | KATE MOSS a8aa941e-19d9-465f-90e7-57d2eca8fdae | Q2 | KATE MOSS | 25988 | CVS HEALTH | 2018 | second_quarter | PHA | Legislation impacting PBMs and drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-16T14:26:07.193000-04:00 | |
| 2146007 | COVINGTON & BURLING LLP a21baaab-a3ce-4a40-8bd8-f6a0f0cd38c5 | Q2 | COVINGTON & BURLING LLP | 11195 | FLEXION THERAPEUTICS, INC. | 2018 | second_quarter | PHA | Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies, including FDA Opioid Sparing legislation. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-07-16T19:58:11.467000-04:00 | |
| 2146044 | BROYDRICK & ASSOCIATES 82c4fb08-f794-470e-ad18-b232e762fdaa | Q2 | BROYDRICK & ASSOCIATES | 7268 | EXELA PHARMA SCIENCES | 2018 | second_quarter | PHA | Drug shortages and FDA approval, USTR acceptance. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-16T22:00:42.973000-04:00 | |
| 2146059 | BROYDRICK & ASSOCIATES 55ab0fa2-b224-4604-b5b9-cf2fb0128b8a | Q2 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2018 | second_quarter | PHA | Funding for a new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-07-16T22:25:57.913000-04:00 | |
| 2146669 | PENN AVENUE PARTNERS c326e8f9-b93e-4efe-b9e7-f5730ae07a48 | Q2 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2018 | second_quarter | PHA | Regulatory and legislative issues impacting Alkermes. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-17T11:21:59.680000-04:00 | |
| 2147211 | PENN AVENUE PARTNERS 6df2a6d7-431d-4b31-8a40-fbea42aa0392 | Q2 | PENN AVENUE PARTNERS | 400918672 | PURDUE PHARMA L.P. | 2018 | second_quarter | PHA | Monitoring legislative and regulatory activities impacting the pharmaceutical industry. | SENATE | 60000 | 0 | 0 | 2018-07-17T13:28:37.180000-04:00 | |
| 2147363 | OREGON HEALTH & SCIENCE UNIVERSITY b25b329b-5289-4d82-b83c-4ec925079963 | Q2 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2018 | second_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2018-07-17T13:56:06.293000-04:00 | |
| 2147542 | PUBLIC CITIZEN 0d7bd05b-7e8f-4523-882f-20fc8c940e33 | Q2 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2018 | second_quarter | PHA | S 2011/HR 4138-Medicare Drug Price Negotiation Act, S 974/HR 2212-CREATES Act of 2017, S 124-Preserve Access to Affordable Generics Act, HR 1625-OMNIBUS, opioid addiction data analysis, S 771-Improving access to affordable prescription drugs act, S 252-Medicare Drug Savings act of 2017, S 1369-Stop Price Gouging Act, S 495-Medical innovation and prize fund act, S 1131/HR 2439-FAIR drug pricing act, HR 4117-Competitive Drugs act of 2017, S 771/HR 1776-Improving access to affordable prescription drugs act, S 637-C-THRU Act, S 1347-RxCap Act of 2017, S 1348-SPIKE Act of 2017, HR 5156-Protecting Medicare from Excessive Price Increases Act of 2018, S 2691-Opioid Crisis accountability act of 2018, S 2315-Over the counter drug safety, innovation, and reform act, S 2700/HR 5545-Comprehensive Addiction Resources Emergency (CARE) act, Drug Pricing-Medicare Part D HR 2051-FAST Generics Act of 2017, HR 4116-Transparent Drug Pricing Act, S 2852-Pandemic and All-Hazards Preparedness Act and advancing innovative Act of 2018, | HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR) | 70000 | 0 | 0 | 2018-07-17T14:23:14.657000-04:00 | |
| 2147596 | MERCY HEALTH SYSTEM 89d61425-9096-42cb-9c40-4b3076d7a116 | Q2 | MERCY HEALTH SYSTEM | 40043344 | MERCY HEALTH SYSTEM | 2018 | second_quarter | PHA | Palliative Care 340 B Drug program Health Care Reform | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-07-17T14:30:34.390000-04:00 | ||
| 2147695 | MEHLMAN CONSULTING, INC. 990fee3e-cf44-49b1-a2d8-981067f3bb72 | Q2 | MEHLMAN CONSULTING, INC. | 284950 | BLUE SHIELD OF CALIFORNIA | 2018 | second_quarter | PHA | Issues related to health insurance and prescription drug pricing. S. 974 - The CREATES Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-17T14:59:34.807000-04:00 | |
| 2147784 | ICE MILLER LLP 37908d21-7472-4b71-99db-bc1cf78d32fd | Q2 | ICE MILLER LLP | 67854 | ELI LILLLY AND COMPANY | 2018 | second_quarter | PHA | Issues related to pharmaceutical research and manufacturing | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE,Vice President of the U.S. | 0 | 0 | 2018-07-17T15:13:13.660000-04:00 | ||
| 2147886 | HANCE SCARBOROUGH 30e80492-40c9-4554-be26-2bb65b743eae | Q2 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2018 | second_quarter | PHA | Issues related to the regulation of pharmacy compounding. HR2871 Preserving Patient Access to Compounded Mediations Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-17T15:30:02.983000-04:00 | |
| 2148020 | FLYNN & ASSOCIATES, INC. aca730de-5b84-48dd-8139-3a31cc60ae8c | Q2 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2018 | second_quarter | PHA | Childrens Health Insurance Program Importation of drugs from Canada Medicare Part D - Rebates | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-07-17T15:49:05.737000-04:00 | |
| 2148026 | HANCE SCARBOROUGH 6a2dcf83-b335-439e-a9c7-477a418cec59 | Q2 | HANCE SCARBOROUGH | 17443 | TITAN PHARMACEUTICALS, INC. | 2018 | second_quarter | PHA | Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-07-17T15:50:07.813000-04:00 | ||
| 2148560 | THE D MAJOR GROUP 52f22542-dd19-47f9-a33b-74034852d9f5 | Q2 | THE D MAJOR GROUP | 401103162 | ALLERGAN INC (FORMERLY ACTAVIS INC ) | 2018 | second_quarter | PHA | Monitor issues concerning bioequivalence standards for pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-17T19:28:41.700000-04:00 | |
| 2148841 | MERCURY PUBLIC AFFAIRS, LLC 82ee7781-af3e-48d6-b022-deeec865f56d | 2T | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2018 | second_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 20000 | 0 | 1 | 2018-07-18T08:54:09.487000-04:00 | |
| 2149339 | MERCURY PUBLIC AFFAIRS, LLC e9f00320-32ec-4ae8-b40b-9ece5784f864 | Q2 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | MORRIS AND DICKSON | 2018 | second_quarter | PHA | IT Help RE Improper Prescriptions | Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),Justice, Dept of (DOJ),Office of Natl Drug Control Policy (NDCP),White House Office | 20000 | 0 | 0 | 2018-07-18T10:39:18.023000-04:00 | |
| 2149353 | BALLARD PARTNERS f01d355d-19f5-4125-b7d8-c47accf8e734 | Q2 | BALLARD PARTNERS | 401104288 | LABORATORY CORPORATIONS OF AMERICA HOLDINGS | 2018 | second_quarter | PHA | Clinical Lab Rates | White House Office | 80000 | 0 | 0 | 2018-07-18T10:41:24.023000-04:00 | |
| 2149480 | LUPIN PHARMACEUTICALS INC 84d3cf1b-7bd4-474f-841b-acc48288b066 | Q2 | LUPIN PHARMACEUTICALS INC | 401104766 | LUPIN PHARMACEUTICALS INC | 2018 | second_quarter | PHA | CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis. | HOUSE OF REPRESENTATIVES,SENATE | 99267 | 0 | 0 | 2018-07-18T10:57:17.273000-04:00 | |
| 2149730 | HUSCH BLACKWELL, LLP 928628ca-2c6c-444f-bdd4-62152ac657b0 | Q2 | HUSCH BLACKWELL, LLP | 6303 | ARJ INFUSION SERVICES, INC. | 2018 | second_quarter | PHA | Issues related to home infusion therapy; S.1738 | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-07-18T11:35:22.777000-04:00 | |
| 2149909 | BALLARD PARTNERS 682d76e9-d3e6-485e-8b52-a7884f22787b | Q2 | BALLARD PARTNERS | 401104288 | THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) | 2018 | second_quarter | PHA | 340B Drug Discount Program | 10000 | 0 | 0 | 2018-07-18T12:12:59.860000-04:00 | ||
| 2149943 | PRIME THERAPEUTICS 0aac680c-7183-4d9b-9a27-78b6936b6249 | Q2 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2018 | second_quarter | PHA | H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-18T12:21:23.753000-04:00 | |
| 2150360 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 272f7e14-9aa5-4f4c-b8af-337d3eb2a996 | Q2 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2018 | second_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-18T14:10:26.717000-04:00 | |
| 2150410 | MANATT, PHELPS, AND PHILLIPS 039c1baf-df73-446b-a8db-370adfad8867 | Q2 | MANATT, PHELPS, AND PHILLIPS | 23645 | NEKTAR THERAPEUTICS | 2018 | second_quarter | PHA | FDA oversight of certain pain reliever products | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 21600 | 0 | 0 | 2018-07-18T14:21:55.453000-04:00 | |
| 2150654 | MASSACHUSETTS MEDICAL SOCIETY 29f771f8-cc95-4f89-a75e-ee270ff31e05 | Q2 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2018 | second_quarter | PHA | S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2018-07-18T15:03:50.067000-04:00 | |
| 2151054 | THORSEN FRENCH ADVOCACY LLC 7ed84331-ed97-4676-9373-6a54d23e8994 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | CARDINAL HEALTH, INC. | 2018 | second_quarter | PHA | Issues related to prescription drug abuse. Issues related to pharmaceutical market value. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-18T15:55:33.340000-04:00 | |
| 2151078 | THORSEN FRENCH ADVOCACY LLC 9ca15a68-f7dc-4871-8c47-83f0ae8aabaf | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | HEALTHCARE DISTRIBUTION ALLIANCE | 2018 | second_quarter | PHA | General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-18T15:58:46.577000-04:00 | |
| 2151110 | THORSEN FRENCH ADVOCACY LLC 45f1382b-a0d7-4f80-9b84-5831ffd66901 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2018 | second_quarter | PHA | Issues related to pharmaceutical market value. Issues related to prescription drug abuse. H.R.2212: CREATES Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-18T16:01:04.387000-04:00 | |
| 2151297 | ROCK & ASSOCIATES 710f6e76-c03b-4a78-b0af-2dc397f3d0cb | Q2 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:22:17.483000-04:00 | |
| 2151301 | ROCK & ASSOCIATES e01ba4c5-6e96-46cb-a446-3c3fdc02d3cc | Q2 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:23:22.093000-04:00 | |
| 2151312 | ROCK & ASSOCIATES 1ccd3a09-5cd6-41fa-b1dc-503f5ece4300 | Q2 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:24:26.140000-04:00 | |
| 2151323 | ROCK & ASSOCIATES 6023a7ba-4dea-4aa8-95f3-5e4504492e48 | Q2 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:25:33.173000-04:00 | |
| 2151341 | ROCK & ASSOCIATES 173e6190-ed62-4f0e-a672-f047a547b806 | Q2 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:26:42.860000-04:00 | |
| 2151360 | ROCK & ASSOCIATES 91d44697-aafd-48a7-b577-36ec738eeaee | Q2 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:27:51.093000-04:00 | |
| 2151369 | ROCK & ASSOCIATES c6c3ec8d-5a75-4b3a-9178-a8d1372305f4 | Q2 | ROCK & ASSOCIATES | 33545 | PRECISION PHARMACY | 2018 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-07-18T16:28:54.173000-04:00 | |
| 2151410 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION d3544e17-df36-45cd-8b73-8a1de58c84b9 | Q2 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2018 | second_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 255000 | 0 | 0 | 2018-07-18T16:34:09.750000-04:00 | |
| 2151856 | ACG ADVOCACY c3cc4c8d-332b-44ba-b899-743068779d75 | Q2 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2018 | second_quarter | PHA | Competition Policy Issues. Drug Pricing Policy Issues. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-07-18T17:35:59.727000-04:00 | |
| 2151949 | WEST FRONT STRATEGIES LLC 572189b6-cfcf-4dd8-9aab-f20a8e8f7a0c | Q2 | WEST FRONT STRATEGIES LLC | 401103493 | WALGREEN CO. | 2018 | second_quarter | PHA | Pharmacy and Medically Underserved Areas Enhancement Act (S. 109 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas; issues related to opioids; H.R. 3528 and S. 2460, the "Every Prescription Conveyed Securely Act." | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-07-18T17:45:34.667000-04:00 | |
| 2152032 | HOOPER, LUNDY & BOOKMAN, P.C. 92683c5b-e7cb-4e3a-9bf0-56bca99ce957 | Q2 | HOOPER, LUNDY & BOOKMAN, P.C. | 401020884 | BROWN RUDNICK, LLP, ON BEHALF OF PRIME THERAPEUTICS | 2018 | second_quarter | PHA | H.R. 5343-Prescription Transparency Act of 2018; S. 2554-Patient Right to Know Drug Prices Act | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-07-18T18:09:20.823000-04:00 | |
| 2152397 | RAMPY NORTHRUP LLC a1102fd5-e517-4f2f-b0fc-cd9e572120ff | Q2 | RAMPY NORTHRUP LLC | 401103289 | ACADEMY OF MANAGED CARE PHARMACY | 2018 | second_quarter | PHA | Dissemination of pharmacoeconomic information. Implementation of 21st Century Cures Act (P.L.114-255). H.R.2026, Pharmaceutical Information Exchange Act. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-18T21:55:41.180000-04:00 | |
| 2152448 | GREENBERG TRAURIG, LLP 9b581e8d-f6c6-40e7-9c5b-5c07f1e0489c | Q2 | GREENBERG TRAURIG, LLP | 16896 | VHG LABS, INC. | 2018 | second_quarter | PHA | Administrative and legislative monitoring and outreach on issues related to pharmaceutical reference standards. | Food & Drug Administration (FDA),SENATE | 60000 | 0 | 0 | 2018-07-18T22:17:05.997000-04:00 | |
| 2152493 | THORN RUN PARTNERS ba16267e-73c8-45ba-98a4-a1379547739f | Q2 | THORN RUN PARTNERS | 400534596 | EXPRESS SCRIPTS, INC. | 2018 | second_quarter | PHA | Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-18T22:45:32.733000-04:00 | |
| 2152743 | BUCHANAN INGERSOLL & ROONEY PC b6646789-5c84-4ae7-a86a-ac7481daaff8 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | ANI PHARMACEUTICALS, INC. | 2018 | second_quarter | PHA | Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-19T05:51:08.167000-04:00 | |
| 2152755 | BUCHANAN INGERSOLL & ROONEY PC 6a17de15-4dcc-4677-a9b9-a76a20b343c5 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | LIPOCINE | 2018 | second_quarter | PHA | Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-07-19T06:02:14.670000-04:00 | |
| 2152770 | BUCHANAN INGERSOLL & ROONEY PC 4566c26e-87e8-4c56-a1e9-ea71bf3a9c6b | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | NOVUM PHARMA | 2018 | second_quarter | PHA | Federal government relations service and strategy relating to pricing issues affecting the pharmaceutical industry | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-19T06:22:21.953000-04:00 | |
| 2152874 | VAN SCOYOC ASSOCIATES 6aa0a19f-e5a8-4cea-8322-23853722b47e | Q2 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2018 | second_quarter | PHA | Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-07-19T08:12:05.263000-04:00 | |
| 2152931 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. e4360ff6-9dae-4f62-a264-e99a4ea0a098 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2018 | second_quarter | PHA | HR 1409, Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2018-07-19T08:40:31.937000-04:00 | |
| 2152959 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 16306201-da7e-42e1-8d5e-f8b6da61435a | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2018 | second_quarter | PHA | Issues related to the 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-19T08:43:41.187000-04:00 | |
| 2152971 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ced4bf17-4f4f-4b85-b6bc-05aa05afc07c | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2018 | second_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2018-07-19T08:47:46.563000-04:00 | |
| 2152976 | UC HEALTH 20f2b75c-04a1-455c-86b8-32c075261e82 | Q2 | UC HEALTH | 401103195 | UC HEALTH | 2018 | second_quarter | PHA | 340b program, drug pricing | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-07-19T08:47:47.703000-04:00 | ||
| 2152984 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 0b196d8b-7749-4f1d-9aca-61139dea2e96 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2018 | second_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2018-07-19T08:49:52.720000-04:00 | |
| 2153261 | UNIVERSITY OF IOWA f606de44-3f64-44de-946d-e82fc5dca490 | Q2 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2018 | second_quarter | PHA | FY 19 appropriations for NIH Support for 340B program | Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT) | 40000 | 0 | 0 | 2018-07-19T09:57:52.447000-04:00 | |
| 2153783 | FTI GOVERNMENT AFFAIRS 12254b2d-7c89-4ee1-87c0-e5db5d4f6ac5 | Q2 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2018 | second_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-07-19T10:52:55.860000-04:00 | |
| 2153846 | GREATER NEW YORK HOSPITAL ASSOCIATION 5de849e0-3940-40e2-af47-f9ffdea65a6f | Q2 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2018 | second_quarter | PHA | Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support) Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Raise awareness about injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Supported legislation to increase competition in the drug marketplace, the CREATES Act (S. 974) (support) | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 610000 | 0 | 0 | 2018-07-19T10:57:22.563000-04:00 | |
| 2154023 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 16e4547a-d793-41a9-a8b5-a2b5c853e79e | Q2 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2018 | second_quarter | PHA | Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Opioid Abuse - General issues related to opioid abuse (HR6, S 2838, S 2837, S 3120, S 2680); Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 327990 | 0 | 0 | 2018-07-19T11:12:53.517000-04:00 | |
| 2154532 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION d5fb409d-678d-47d0-81c3-0db7b7d95006 | Q2 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2018 | second_quarter | PHA | Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Proposed Part D Rule and accompanying RFI. Issues related to Medicaid Provider Enrollment. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 766889 | 0 | 0 | 2018-07-19T11:52:15.007000-04:00 | |
| 2155151 | FORBES-TATE 99778def-a5e3-44c6-90ce-35b112694e34 | Q2 | FORBES-TATE | 400976792 | PHRMA | 2018 | second_quarter | PHA | Issues pertaining to Rx Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-07-19T12:59:53.460000-04:00 | |
| 2155500 | ACG ADVOCACY 7af34ab0-a302-4d86-a90e-bf5fda6afca0 | Q2 | ACG ADVOCACY | 2057 | GENENTECH INC | 2018 | second_quarter | PHA | Drug pricing issues. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-19T13:27:00.807000-04:00 | |
| 2155571 | WINNING STRATEGIES WASHINGTON b21ff906-fe7b-4d76-9cf4-b1fa14efa317 | Q2 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2018 | second_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-07-19T13:32:33.103000-04:00 | |
| 2155708 | POLARIS GOVERNMENT RELATIONS, LLC 83bb63e4-2762-4b5b-ad4e-8fda3838e432 | Q2 | POLARIS GOVERNMENT RELATIONS, LLC | 307730 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2018 | second_quarter | PHA | Provide advice and counsel on matters impacting the generic pharmaceutical industry such as generic labeling and access; CREATES Act, S. 3056 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-07-19T13:47:32.717000-04:00 | |
| 2156070 | ELI LILLY AND COMPANY 61df05e4-364e-4d49-b49d-9215926adac5 | Q2 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2018 | second_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1490000 | 0 | 0 | 2018-07-19T14:20:45.610000-04:00 | |
| 2156393 | ACG ADVOCACY 9d5ad850-5797-459b-bd30-c98ac06ee415 | Q2 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2018 | second_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-07-19T14:41:30.050000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);